NCT03897283 - Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

December 31, 2021

Conditions

Advanced Solid Tumors

Interventions

DRUG

TQB2450

TQB2450 1200 mg administered IV on Day 1 of each 21-day cycle

DRUG

Anlotinib

Anlotinib capsules given orally in fasting conditions, dose ranging from 8 mg to 12 mg once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21). Initial dose is 10 mg. If there are no patients with DLT in first treatment cycle , begin to explore dose of 12 mg. If there are 2 or more patients in 3 patients with DLT, 8 mg dose is to explore.

Trial Locations (1)

Unknown

RECRUITING

Jilin Cancer Hospital, Changchun